Dova is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates where there is a high unmet medical need. DOPTELETÂŽ (avatrombopag) is an orally administered thrombopoietin receptor agonist that we are developing for the treatment of thrombocytopenia across many different patient types. Source
No articles found.
We are an innovative biopharmaceutical company developing therapies to treat the m...
We are an innovative biopharmaceutical company ...
Anixa is focused on harnessing the bodyâs immune system in the fight against can...
Anixa is focused on harnessing the bodyâs imm...
Halo gives scientists and academics opportunities to connect with industry partner...
Halo gives scientists and academics opportuniti...
Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet ne...
Neurocarrus is developing a breakthrough therap...
Join the National Investor Network and get the latest information with your interests in mind.